Modern medicine tends to approach chronic diseases as distinct entities: cardiovascular disease, diabetes, neurodegeneration, autoimmunity, cancer. Each is assigned its own specialty, biomarkers, and treatment algorithms.
Yet in real-world clinical practice, these conditions rarely occur in isolation.
Patients with metabolic disease often develop cardiovascular disease. Neuroinflammatory disorders coexist with autoimmune conditions. Cancer frequently arises on a background of chronic inflammation, metabolic dysfunction, and tissue fragility.
This recurring pattern raises a fundamental question:
What if these diseases are not separate problems, but different expressions of a shared upstream failure?
This question is central to Systemic Leaky Barrier Syndrome (SLBS), a systems-level framework that I first proposed and defined to describe shared barrier failure across chronic disease.
SLBS: not a diagnosis, but a shared disease pathway
SLBS does not describe a single disease.
It describes a common systems-level pathway through which many chronic diseases develop and progress.
Across organ systems, biological barriers — intestinal, vascular, blood–brain, pulmonary, renal, hepatic, and stromal — rely on the same foundational requirements:
intact structural proteins and extracellular matrix
sufficient cellular energy supply
balanced redox signaling and antioxidant capacity
ongoing micronutrient availability
effective tissue repair mechanisms
When these requirements are chronically compromised, barriers do not simply become “leaky.”
They lose the ability to fully repair.
SLBS captures this state of systemic barrier vulnerability, in which multiple tissues gradually lose compartmental integrity under sustained metabolic, inflammatory, and oxidative stress.
How one pathway produces many diseases
Seen through the SLBS lens, different chronic diseases represent different downstream expressions of the same upstream process:
In the gut, SLBS manifests as increased permeability, immune activation, and dysbiosis
In the vasculature, it appears as endothelial dysfunction, arterial stiffening, and atherosclerosis
In the brain, it contributes to blood–brain barrier disruption and neuroinflammation
In the kidneys and lungs, it presents as filtration and exchange failure
In connective tissues, it leads to structural fragility and impaired healing
The organ involved determines the clinical label — but the pathway driving damage is shared.
This helps explain why treating one organ in isolation so often fails to alter long-term disease trajectory.
Cancer as a late-stage expression on the same pathway
Cancer fits naturally within this framework.
Rather than viewing cancer solely as an isolated genetic event, SLBS allows cancer to be understood as an advanced, invasive expression of systemic barrier failure.
As epithelial, endothelial, stromal, immune, and extracellular matrix boundaries progressively lose integrity:
tissue compartmentalization breaks down
local microenvironments become chronically inflamed and oxidatively stressed
normal differentiation and repair signals fail
In this context, malignant transformation reflects not only abnormal cellular proliferation, but loss of boundary control — enabling invasion, pathologic angiogenesis, immune evasion, and metastasis.
Importantly, these processes do not suddenly appear at the moment of diagnosis.
They represent a late convergence of mechanisms that have often been active — and clinically visible — for years or decades.
Why this matters in practice
If chronic diseases are viewed as separate, unrelated conditions, clinical care naturally focuses on:
managing symptoms
suppressing downstream pathways
reacting to late-stage organ failure
SLBS shifts attention upstream, toward shared vulnerabilities that cut across diagnoses:
declining repair capacity
cumulative oxidative and redox stress
micronutrient depletion
mitochondrial energy insufficiency
iron-driven tissue injury
chronic inflammatory signaling
Recognizing SLBS does not replace disease-specific diagnosis or treatment.
But it changes how clinicians prioritize risk, timing, and prevention, especially in patients with multiple coexisting conditions.
From disease labels to pathway thinking
Orthomolecular medicine has long emphasized that health depends on structural integrity, nutritional sufficiency, redox balance, and upstream causality.
SLBS provides a modern systems framework that integrates these principles into a single explanatory pathway linking metabolic disease, cardiovascular disease, neuroinflammation, autoimmunity, and cancer.
Seen this way, many chronic diseases are not independent failures to be managed one at a time.
They are different downstream outcomes of the same unresolved upstream process.
Understanding that process — and intervening earlier — is the real frontier of chronic disease medicine.
Editor’s note
Editor’s note
This article builds on my recent preprint, Systemic Leaky Barrier Syndrome (SLBS): A Systems-Level Framework for Chronic Disease (Preprints, 2026), which introduces SLBS as a unifying systems-medicine framework for chronic disease. The SLBS concept is part of my broader 21st-Century Medicine framework, which organizes chronic disease around shared upstream mechanisms, including the ten categories of root drivers.
Future posts will explore how SLBS applies to cancer biology, cardiovascular disease progression, and metabolic dysfunction.
About the Author
Richard Z. Cheng, MD, PhD is Editor-in-Chief of the Orthomolecular Medicine News Service (OMNS). He is a U.S.-trained, NIH-trained, board-certified physician specializing in Integrative Orthomolecular Medicine (IOM), with a clinical focus on integrative oncology, metabolic medicine, and complex chronic disease.
Dr. Cheng is a Hall of Fame inductee of the International Society for Orthomolecular Medicine and a Fellow of the American Academy of Anti-Aging and Regenerative Medicine (A4M). He has played an active role in advancing nutrition-based, root-cause approaches to chronic disease, including co-founding the China Low Carb Medicine Alliance and serving as an expert reviewer for the South Carolina Board of Medical Examiners.
He is the author of the forthcoming book 21st Century Medicine: Integrative Orthomolecular Medicine for Chronic Disease Reversal and Longevity, which synthesizes systems-medicine insights developed over decades of clinical practice and biomedical research.
Dr. Cheng offers international consultations focused on systems-level evaluation and root-cause management of complex chronic diseases.
Contact
For professional or academic inquiries, Dr. Cheng may be reached at richzc@gmail.com.
This article is great and makes a lot of sense.
On our farm, we butcher many animals, mostly hogs and cows we raise in the woods and on pasture forage, and the pristine appearance of their guts and organs is our standard. Occasionally, we butcher animals from other farms that were fed soy or even GMO feed. The most noticeable difference is the fragile connective tissues inside animals we don’t raise. GMO feed and other stresses also causes visible gut inflammation that looks like perforations all down the intestines and often lesions in the liver. Hogs are harvested at under one year of age. Cows 2-3. I’m sure these same effects are seen in humans raised on the depleted and toxic food system.
Hi Dr Cheng,
I am not medically trained, however I Fully Agree with this report.
Even from the mid-1980s, I had seen signs of this SLBS amongst people I knew (both friends and family).
Sadly, the Increase in such linked illnesses is ***Now becoming more Exponential.***